U.S. Markets closed

Why Derma Sciences (DSCI) Could Be Positioned for a Surge

Zacks Equity Research

Derma Sciences Inc. DSCI is a medical device company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on DSCI’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Derma Sciences could be a solid choice for investors.

Current Quarter Estimates for DSCI

In the past 30 days, 1 estimate has gone higher for Derma Sciences while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 10 cents a share 30 days ago, to a loss of 8 cents today, a move of 20%.

Current Year Estimates for DSCI                  

Meanwhile, Derma Sciences’ current year figures are also looking quite promising, with 1 estimate moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss of 30 cents per share 30 days ago to a loss of 20 cents per share today, an increase of 33.3%.

Bottom Line

The stock has also started to move higher lately, adding 9.6% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #2 (Buy) stock to profit in the near future.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
DERMA SCIENCES (DSCI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.